SCHEMBL8007271

SCHEMBL8007271

Cc1ccc(N2CCN(C(=O)COc3ccc4c(c3)CCC(=O)N4)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
GLA P06280 1/20 0.58
ALOX15 P16050 1/20 0.58
POLB P06746 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KCNH2 Q12809 2/20 0.55
OGT O15294 1/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
USP2 O75604 2/20 0.51
DRD2 P14416 3/20 0.50
HTT P42858 3/20 0.50
NR3C1 P04150 1/20 0.50
PGR P06401 1/20 0.50
SLC6A4 P31645 1/20 0.50
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024131 0.90 KCNH2 (0.67) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL31718509 0.88 ENPP2 (0.58) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL15451474 0.88 NPC1 (0.54) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL2021199 0.86 KCNH2 (0.53) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL2018529 0.86 GRIN1 (0.58) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL8008833 0.82 ENPP2 (0.58) ALDH1A1SMN1; SMN2POLBTDP1KCNH2
SCHEMBL10571129 0.82 DRD2 (0.68) KCNH2DRD2SLC6A4DRD4DRD3
SCHEMBL2017577 0.81 KCNH2 (0.67) ALDH1A1SMN1; SMN2POLBTDP1KCNH2
SCHEMBL2025475 0.80 KCNH2 (0.65) ALDH1A1MAPK1SMN1; SMN2GLAALOX15
SCHEMBL2020793 0.80 KCNH2 (0.82) ALDH1A1SMN1; SMN2POLBTDP1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170334-B1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION UNIV EMORY (US) 2021-03-17 EP disclosed
US-9079852-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2015-07-14 US disclosed
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection LIOTTA DENNIS C (US) 2014-01-30 US disclosed
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
WO-2009137843-A2 NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS EMORY UNIVERSITY (US) 2009-11-12 WO disclosed
WO-2009006437-A1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION EMORY UNIVERSITY (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 ALDH1A1 2668/4885MAPK1 1307/4885SMN1; SMN2 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.